Furui Co.,Ltd(SZ:300049)2022-12-07 09:36Group 1: Strategic Partnerships and Investments - The company introduced three strategic shareholders, including KKR, Aobo, and Luxembourg, through capital increase and equity transfer, while maintaining control over Echosens [1] - The aim is to enhance technology and product offerings, focusing on becoming a leading company in liver assessment and diagnosis globally [2] Group 2: APP Development and User Engagement - The "Love Liver" health management APP is set to launch in May, with a target of developing 100,000 new members in the first phase and potentially activating an additional 400,000 users later [2] - The APP will facilitate communication between doctors and patients, allowing for direct interaction and feedback, enhancing patient experience and engagement [2] Group 3: Revenue and Financial Projections - Revenue from the "Love Liver" centers was approximately 15 million RMB last year, with projections of 80 million RMB for the current year [4] - The company aims to diversify its revenue streams into three areas: pharmaceutical sales, medical devices, and healthcare services, with a target of achieving a balanced revenue distribution over the next decade [4] Group 4: Market Potential and Competition - The liver disease market is significant, especially with the inclusion of fatty liver disease, which is reversible and has a large potential market [5] - The company acknowledges competition in the medical device sector but views it as a motivator for improving sales efforts and market focus [5]